Product Information
Contents: Phycoerythrin (PE) anti-human TWEAK
Catalog Number: 12-9915
Sizes: 25 tests, 100 tests
Formulation: Phosphate buffer pH 7.2, 500 mM NaCl, 0.09% NaN3, 0.2% BSA
Storage Conditions: Store at 4°C. DO NOT FREEZE. LIGHT-SENSITIVE MATERIAL.
Clone: CARL-1
Isotype: Mouse IgG3, κ
|
|
|
Questions? Please consult our answers to frequently asked questions at
http://www.ebioscience.com/faq.
Description
The CARL-1 monoclonal antibody reacts with human TWEAK, a type II transmembrane TNF superfamily member with high identity to TNF in its extracellular portion. TWEAK transcript is expressed broadly in many adult and fetal tissues, however, the staining of human peripheral blood mononuclear cells with monoclonal antibodies shows a more restricted pattern. While freshly isolated PBMCs do not express detectable levels of TWEAK on their surface, IFN-γ-stimulated blood monocytes rapidly upregulate TWEAK surface expression. TWEAK is expressed as membrane bound and secreted forms. Interaction of TWEAK with its counter-receptor promotes secretion of IL-8, activation of NF-κB, proliferation of endothelial cells, and apoptosis in a number of human cell lines. Initially, DR3 was thought to be a receptor for TWEAK, but further studies have shown that TWEAK could induce apoptosis via receptors distinct from DR3. While TWEAK exhibits overlapping signaling functions to TNF, it is generally less effective in inducing apoptosis, giving rise to its name, TNF-like weak inducer of apoptosis. For detection of human TWEAK by sandwich ELISA, a combination of purified CARL-2 for capture and biotinylated CARL-1 for detection is recommended.
Applications Reported
For research use only, not for diagnostic or therapeutic use. The CARL-1 antibody has been reported for use in flow cytometric analysis.
Applications Tested
The CARL-1 antibody has been pre-titrated and tested by flow cytometric analysis of transfected cells and IFN-γ-stimulated human PBMCs. This can be used at 20 μl per 100 μl blood (or per 1 million cells in 100 μl total staining volume).
References
Nakayama, M., N. Kayagaki, et al. (2000). "Involvement of TWEAK in Interferon {gamma}-stimulated Monocyte Cytotoxicity."
J. Exp. Med. 192(9): 1373-1380.
Chicheportiche, Y., P. R. Bourdon, et al. (1997). "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis."
J Biol Chem 272(51): 32401-10.
Kaplan, M. J., D. Ray, et al. (2000). "TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages [In Process Citation]."
J Immunol 164(6): 2897-904.
Lynch, C. N., Y. C. Wang, et al. (1999). "TWEAK induces angiogenesis and proliferation of endothelial cells."
J Biol Chem 274(13): 8455-9.
Schneider, P., R. Schwenzer, et al. (1999). "TWEAK can induce cell death via endogenous TNF and TNF receptor 1."
Eur J Immunol 29(6): 1785-92.
Related Products
Cat.
12-4742 PE Mouse IgG3 Isotype Control
Cat.
14-8916 Recombinant Human TWEAK
Cat.
14-9916 Affinity Purified anti-human TWEAK (clone CARL-2)